State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, People's Republic of China.
Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, People's Republic of China.
Biochim Biophys Acta Mol Basis Dis. 2021 Mar 1;1867(3):166037. doi: 10.1016/j.bbadis.2020.166037. Epub 2020 Dec 9.
Hypertension is one of the most prevalent cardiovascular diseases worldwide. However, in the population of resistant hypertension, blood pressure is difficult to control effectively. Moreover, antihypertensive drugs may have adverse effect currently. Hence, new therapeutic targets and treatments are needed to uncovered and exploited to control hypertension and its comorbidities. In the past, classical drug targets, such as the aldosterone receptor, aldosterone synthase, and ACE2/angiotensin 1-7/Mas receptor axis, have been investigated. Recently, vaccines and drugs targeting the gastrointestinal microbiome, which represent drug classes, have also been investigated for the management of blood pressure. In this review, we summarized current knowledge on classical and new drug targets and discussed the potential utility of new drugs in the treatment of hypertension.
高血压是全球最普遍的心血管疾病之一。然而，在难治性高血压患者人群中，血压难以得到有效控制。此外，目前的降压药物可能会产生不良反应。因此，需要发现和利用新的治疗靶点和治疗方法来控制高血压及其合并症。过去，人们研究了经典的药物靶点，如醛固酮受体、醛固酮合酶和 ACE2/血管紧张素 1-7/Mas 受体轴。最近，人们还研究了针对胃肠道微生物组的疫苗和药物，这些药物代表了药物类别，也被用于管理血压。在这篇综述中，我们总结了目前关于经典和新型药物靶点的知识，并讨论了新型药物在高血压治疗中的潜在应用。
